Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT06282874 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Brain Metastases
Leptomeningeal Metastasis

Interventions

DRUG: Lorlatinib

Sponsor

Guangdong Association of Clinical Trials